Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Sudden death; This is a spontaneous report from a contactable physician downloaded from the regulatory authority-WEB, regulatory authority number FR-AFSSAPS-MA20211056. A 66-year-old male patient received bnt162b2 (COMIRNATY), first dose via intramuscular on 17Feb2021 (Batch/Lot Number: EP9598) as single dose, then second dose via intramuscular on 17Mar2021 (Batch/Lot Number: ET3620) as single dose for COVID-19 immunization. Medical history included diabetes, coronary artery disease, Arteriopathy obliterans of the lower limbs with amputation of both legs, retinopathy with blindness in one eye, dialysis (last dialysis on 19Mar2021), and arterial hypertension. Concomitant medication included irbesartan (APROVEL); atorvastatin; bisoprolol; urapidil (EUPRESSYL [URAPIDIL]); sodium polystyrene sulfonate (KAYEXALATE); insulin detemir (LEVEMIR); nicardipine hydrochloride (LOXEN [NICARDIPINE HYDROCHLORIDE]); clopidogrel bisulfate (PLAVIX); and saccharated iron oxide (VENOFER), all for unspecified indication. The patient had sudden death following the second vaccination of bnt162b2. The patient underwent lab tests and procedures which included blood potassium: 6 on an unspecified date. The patient died on 21Mar2021. It was not reported if an autopsy was performed. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: Sudden death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166